Drug Search Results
More Filters [+]

AMG-811

Alternative Names: amg-811, amg811, amg 811
Latest Update: 2014-11-14
Latest Update Note: Clinical Trial Update

Product Description

AMG 811is a human IgG1 monoclonal antibody that selectively targets and neutralizes human IFN- g.

Mechanisms of Action: IFNG Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AMG-811

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lupus Erythematosus, Discoid|Lupus Erythematosus, Cutaneous|Glomerulonephritis|Lupus Erythematosus, Systemic|Lupus Nephritis|Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00818948

P1

Completed

Lupus Erythematosus, Systemic|Lupus Nephritis|Glomerulonephritis

2014-06-01

NCT01510951

P1

Completed

Psoriasis

2012-10-01

NCT01164917

P1

Terminated

Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic

2012-09-01

NCT02291588

P1

Completed

Lupus Erythematosus, Systemic

2010-03-01

Recent News Events

Date

Type

Title